In a post hoc secondary analysis of SOUL (9650 adults with type 2 diabetes and ASCVD and/or CKD), oral semaglutide vs placebo gave sustained improvements in HbA1c, weight, systolic BP, hsCRP and some lipids; LDL-C and diastolic BP did not differ.
Secondary analysisn = 9,650
Mulvagh et al. Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial